Drug Profile
BAY 866150
Alternative Names: BAY 86-6150; BAY VII; Factor VIIa - Bayer; Maxy 968; MAXY-VIILatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Maxygen
- Developer Bayer HealthCare
- Class Blood coagulation factors; Coagulants; Recombinant proteins
- Mechanism of Action Factor VIIa stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haemophilia A; Haemophilia B
Most Recent Events
- 20 Aug 2013 Discontinued - Phase-I for Haemophilia A in United Kingdom (Parenteral)
- 20 Aug 2013 Discontinued - Phase-I for Haemophilia B in United Kingdom (Parenteral)
- 20 Aug 2013 Discontinued - Phase-II/III for Haemophilia A in Bulgaria, Poland, Singapore, South Korea, South Africa and Ukraine (Parenteral)